Auto, pharma stocks likely to see upsides

STOCK MARKET WATCh

Image
Newswire18 New Delhi/ Mumbai
Last Updated : Jan 29 2013 | 1:55 AM IST

Continued buying prompted by softening of inflation is likely to keep frontline automobile counters in the green next week, analysts said. “Investors are likely to make purchases at lower levels. However, much would depend on the overall market sentiment,” Mumbai-based analysts said.

This is the first time in 28 weeks that the index had fallen week-on-week. The finance ministry, too, in its statement said there are some early signs of moderation of inflation.

Rising inflation has led to sharp falls in interest rate-sensitive stocks such as automobile counters as investors feared tightening of monetary policy to control inflation.

The Reserve Bank of India has already raised short-term benchmark rate by 125 basis points and cash reserve ratio by 150 basis points since beginning of the current financial year (2008-09) to tame inflation.

Automobile stocks would also see positive effect of softening in global crude oil prices.

The Indian crude oil basket on Thursday rose 22 cents a barrel to $112.19. It has averaged $113.12 so far this month, down about 14.6 per cent from July’s average of $132.47.

The pharma sector stocks are seen range-bound with a positive bias next week, dealers said. Shares of Cipla and Sun Pharmaceutical are seen up, while Ranbaxy and GlaxoSmithKline Pharma are seen down on charts, said Dharmesh Shah, technical analyst with ICICI Direct.

Technically, Cipla is seen positive with resistance at Rs 245, Shah said.

The company was in the news this week, giving an update on its plans for the year after its annual general meeting. Based on this, Citigroup has recommended ‘sell’ on Cipla on a possible slowdown in revenue growth.

Cipla had reiterated its revenue guidance of 12-15 per cent in 2008-09, which implies a slowdown in next three quarters, as the company reported 32 per cent growth in April-June, Citigroup report said.

Sun Pharma, riding on favourable court verdict on its offer for Taro Pharma, is likely to extend its gains next week, with resistance at Rs 1,525 and support at Rs 1,396.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 31 2008 | 12:00 AM IST

Next Story